Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...

Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...

Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice.

CHICAGO – PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair-deficient (dMMR) cancers, ...

Sixteen patients with mismatch repair–deficient, locally advanced rectal cancer were enrolled in a pilot study in which 6 months of neoadjuvant anti–PD-1 therapy was to be followed by surgical ...

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite ...

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

Bowel cancer cells have the ability to regulate their growth using a genetic on-off switch to maximize their chances of survival, a phenomenon that's been observed for the first time by researchers at ...